← Back
United Therapeutics
UTHR · listed on Nasdaq · worth $25.36 billion
$592.84
+0.91% on Oct 26
Since Sep 30, 2026, no insider has bought United Therapeutics stock. They sold it 233 times, $87.75 million in all. One member of Congress reported trading United Therapeutics in the last year.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
39.2M shares
91% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
Since Sep 30, 2026, two insiders sold United Therapeutics stock and none bought. Every one of the 233 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Martine A. Rothblatt, Chairperson & CEO.
Planned sales
Form 144 notices filed for United Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Paul A. Mahon filed to sell 8,300 shares on 15 Oct; sold 8,300 by 15 Oct10b5-1 plan adopted 11 Aug 2025 · Notice on SEC.gov
Executive Paul A. Mahon filed to sell 8,300 shares on 1 Oct; sold 8,300 by 1 Oct10b5-1 plan adopted 11 Aug 2025 · Notice on SEC.gov
CEO Martine A. Rothblatt filed to sell 209,000 shares on 1 Oct; sold 171,000 by 23 Oct10b5-1 plan adopted 21 Nov 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of United Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateRothblatt Martine A5.3%Aug 14
US Congress
Members of Congress who reported trading United Therapeutics in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for United Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 26SoldMartine A. RothblattOct 26 · Traded Oct 23 · Chairperson & CEO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family740 @ $588.00$435.1K
Oct 26SoldMartine A. RothblattOct 26 · Traded Oct 23 · Chairperson & CEO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family542 @ $586.93$318.1K
Oct 26SoldMartine A. RothblattOct 26 · Traded Oct 23 · Chairperson & CEO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family778 @ $585.99$455.9K
Oct 26SoldMartine A. RothblattOct 26 · Traded Oct 23 · Chairperson & CEO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family676 @ $584.77$395.3K
Oct 26SoldMartine A. RothblattOct 26 · Traded Oct 23 · Chairperson & CEO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family427 @ $583.83$249.3K
228 more with Pro →Analysts, earnings and news
Analysts' price target
$665.23 average
13 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q1 '26$5.82 a share−$1.04
Q4 '25$7.70 a share+$0.94
Q3 '25$7.16 a share+$0.20
Q2 '25$6.41 a share−$0.53